Teva Pharmaceutical Industries sues CMS over Medicare drug pricing negotiations policy, claiming agency has unchecked ...
Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.6 billion, has been navigating a complex landscape of legal ...
Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, ...
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar ...
Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days ...
Pharmaceutical companies brace for the upcoming Trump administration. Teva Pharmaceuticals (TEVA) CEO Richard Francis joins ...
Timing Trades in Teva Pharmaceutical Industries Limited American Depositary Shares TEVA can be Risky if you Don't Have ...
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
Piper Sandler raised the firm’s price target on Teva (TEVA) to $30 from $23 and keeps an Overweight rating on the shares after meeting with ...
Teva Pharmaceutical collaborates with Klinge Biopharma and Formycon AG to commercialize Formycon's biosimilar candidate to ...
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...